Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Clinical Trials in Guangzhou, Guangdong

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma